SecBot SecBot
8-K ·Filed Aug 6, 2026

VTRS

Viatris Inc
BULLISH
Impact 7/10
Horizonweeks Processed3mo ago SEC0001792044-26-000037
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The guidance raise and strong beat confirm improving operational momentum and balance sheet deleveraging. However, the Nashik supply disruption creates H2 uncertainty, monitor management's remediation progress and any further guidance revisions. The Gwyn Lo launch and Tyrvaya monetization add pipeline value but are not near-term revenue drivers. The stock may re-rate on the combination of earnings growth and debt reduction, but the $100-150M revenue headwind from Nashik limits upside until resolved.

DirectionBullish
Confidencehigh
Horizonweeks

Tyrvaya

● Neutral Named in this 8-K
Impact
Phase
Approved
Time to market
Already approved and commercialized since October 2021.
Next catalyst
None dated

What to watchTyrvaya is now owned by Harrow (HROW), not Viatris (VTRS). The next catalyst is Harrow's commercial execution: Tyrvaya closed on October 5, 2026, so its contribution to Harrow's Q4 2026 and full-year 2027 results will be the key metric to watch. Harrow expects Tyrvaya to add more than $30M in 2027 revenue. For Viatris, Tyrvaya is a divested non-core asset with no further impact.

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$16.29
T+0 close · Aug 6, 2026 · via day close
Latest settled
+16.85%
T+60 · $19.04
Vs SPY
+18.52%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 6 $16.29entry
  2. T+1 · 3mo ago +0.86%α +0.25% · $16.43
  3. T+5 · 3mo ago −1.53%α −2.75% · $16.04
  4. T+20 · 3mo ago +3.99%α +3.39% · $16.94
  5. T+60 · 18d ago +16.85%α +18.52% · $19.04
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Viatris Q2 2026 earnings beat consensus with adjusted EPS of $0.69 (15% above $0.60 est) and total revenue of $3.76B (+5% YoY, 2.4% above consensus). The company raised midpoints of all 2026 guidance metrics, revenue to $14.75B, adjusted EBITDA to $4.4B, adjusted EPS to $2.52, and free cash flow to $2.2B, while reducing gross leverage to 2.9x and returning $550M to shareholders. Material headwinds from the Nashik facility disruption ($100-150M H2 revenue impact) are partially offset by FDA approval of Gwyn Lo and the Tyrvaya sale.

Key Financial Metrics

EPS
$0.69
est $0.60 · +15.0%
Revenue
$3.8B
est $3.7B · +2.4% · +5.0% YoY
Rating
strong beat
Guidance
$14.55B-$14.95B
raised
Free Cash Flow
$329.0M
Gross Margin
38.8%

Key Facts

  • Q2 adjusted EPS $0.69 vs consensus $0.60 (+15% beat)
  • Total revenue $3.76B vs consensus $3.67B (+2.4% beat); reported growth +5%, operational +4%
  • Raised 2026 guidance midpoints: revenue $14.75B (from $14.70B), adj. EBITDA $4.40B (from $4.30B), adj. EPS $2.52 (from $2.40), FCF $2.20B (from $2.15B)
  • Gross leverage ratio reduced to 2.9x; $900M debt repaid, refinanced with €650M notes
  • Returned ~$550M to shareholders YTD including $270M in share repurchases at $16.42 avg
  • FDA approved Gwyn Lo contraceptive patch; signed Tyrvaya sale for $30M upfront + $70M milestones
  • Nashik facility disruption expected to impact $100-150M of H2 2026 total revenue
  • Adjusted EBITDA $1.19B (+10% reported, +8% operational); free cash flow ex-items $449M in Q2

Financial Impact

Guidance midpoint raise of $0.12 on adjusted EPS (+5%) and $100M on EBITDA (+2.3%) vs. prior guidance, partially offset by $100-150M Nashik revenue headwind

revenueadjusted EPSadjusted EBITDAfree cash flowgross leverage

Risk Factors

  • Nashik facility disruption could be worse than guided $100-150M hit to H2 revenue
  • Generics pricing pressure and competition on key brands (EpiPen, Lyrica, Viagra)
  • Currency headwinds from strong USD (operational growth 3.5% vs reported 5%)
  • Execution risk on new product launches (Gwyn Lo, MR-107A-02) and pipeline milestones

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
65% bullish (17 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001792044-26-000037
Document: vtrs-20260806.htm0001792044-26-000037
Document: 0001792044-26-000037-index-headers.html0001792044-26-000037
Document: 0001792044-26-000037-index.html0001792044-26-000037
Document: 0001792044-26-000037.txt0001792044-26-000037
8-K Data (Synthetic)0001792044-26-000037

US Market Status

Market Open · Closes in 40m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 6, 2026